International Aids Vaccine Initiative Inc, operating under the name Iavi, is located in New York, NY. The organization was established in 1996. According to its NTEE Classification (Q30) the organization is classified as: International Development, under the broad grouping of International, Foreign Affairs & National Security and related organizations. As of 12/2023, Iavi employed 268 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Iavi is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Iavi generated $129.7m in total revenue. This represents relatively stable growth, over the past 9 years the organization has increased revenue by an average of 6.7% each year. All expenses for the organization totaled $132.9m during the year ending 12/2023. While expenses have increased by 7.8% per year over the past 9 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Iavi has awarded 141 individual grants totaling $60,363,299. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS
Describe the Organization's Program Activity:
Part 3 - Line 4a
RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED DOZENS OF HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS, INCLUDING A VACCINE THAT RECENTLY YIELDED PROMISING RESULTS AND IS PART OF AN EXCITING NEW APPROACH TO HIV VACCINE DESIGN. OTHER NOTABLE ACHIEVEMENTS INCLUDE THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE HIV BURDEN IS GREATEST, AND THE FIRST TRIAL OF AN MRNA HIV VACCINE CANDIDATE IN AFRICA. IAVI HAS CONDUCTED MORE THAN 50 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING, COUNSELING SERVICES, AND HEALTH CARE REFERRALS TO MORE THAN 870,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS, LASSA FEVER, MARBURG, EBOLA SUDEN, AND COVID-19, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. IAVI ALSO SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Mark B Feinberg President/ceo | OfficerTrustee | 35 | $719,151 |
Eric Paul Goosby Board Chair | OfficerTrustee | 2 | $0 |
Robert Goldberg Board Treasurer | OfficerTrustee | 2 | $0 |
Linda-Gail Becker Board Member | Trustee | 1 | $0 |
David Blumberg Board Member | Trustee | 1 | $0 |
Jim Connolly Board Member | Trustee | 1 | $0 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Emmes Corporation Clinical Research Studies | 12/30/23 | $1,245,043 |
Australian Biologics Pty Ltd Regulatory Consultant | 12/30/23 | $401,508 |
Wits Health Consort Program Consultant | 12/30/23 | $267,425 |
Armstrong Teasdale Legal Services | 12/30/23 | $241,508 |
Us Medical Equip Cons Inc Equipment Maintenance | 12/30/23 | $219,338 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $70,009,700 |
All other contributions, gifts, grants, and similar amounts not included above | $54,577,973 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $124,587,673 |
Total Program Service Revenue | $2,297,276 |
Investment income | $3,256,766 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | -$494,343 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $129,678,400 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $9,318,320 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $21,937,571 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $2,429,430 |
Compensation of current officers, directors, key employees. | $2,277,452 |
Compensation to disqualified persons | $105,000 |
Other salaries and wages | $36,453,779 |
Pension plan accruals and contributions | $2,954,957 |
Other employee benefits | $4,068,743 |
Payroll taxes | $2,519,684 |
Fees for services: Management | $0 |
Fees for services: Legal | $1,090,452 |
Fees for services: Accounting | $215,651 |
Fees for services: Lobbying | $225,000 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $89,219 |
Fees for services: Other | $798,898 |
Advertising and promotion | $0 |
Office expenses | $850,783 |
Information technology | $1,572,404 |
Royalties | $0 |
Occupancy | $5,859,423 |
Travel | $1,911,741 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $404,539 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $1,545,566 |
Insurance | $410,686 |
All other expenses | $295,486 |
Total functional expenses | $132,896,237 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $0 |
Savings and temporary cash investments | $34,403,229 |
Pledges and grants receivable | $46,434,558 |
Accounts receivable, net | $279,535 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $146,763 |
Net Land, buildings, and equipment | $927,381 |
Investments—publicly traded securities | $33,407,409 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $8,635,068 |
Total assets | $124,233,943 |
Accounts payable and accrued expenses | $9,420,265 |
Grants payable | $11,781,746 |
Deferred revenue | $28,968,880 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $10,139,300 |
Total liabilities | $60,310,191 |
Net assets without donor restrictions | $32,056,013 |
Net assets with donor restrictions | $31,867,739 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $124,233,943 |
Over the last fiscal year, International Aids Vaccine Initiative Inc has awarded $9,190,196 in support to 23 organizations.
Grant Recipient | Amount |
---|---|
THE SCRIPPS RESEARCH INSTITUTE - OSP PURPOSE: RESEARCH & DEVELOPMENT | $3,088,050 |
TEXAS BIOMEDICAL RESEARCH INSTITUTE PURPOSE: RESEARCH & DEVELOPMENT | $1,667,115 |
LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY PURPOSE: RESEARCH & DEVELOPMENT | $592,672 |
EMORY UNIVERSITY PURPOSE: RESEARCH & DEVELOPMENT | $462,130 |
THE UNIVERSITY OF TEXAS MEDICAL BRANCH GALVESTON PURPOSE: RESEARCH & DEVELOPMENT | $453,031 |
BOSTON UNIVERSITY PURPOSE: RESEARCH & DEVELOPMENT | $432,798 |